A study of upadacitinib for eczema in teens and adults
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well upadacitinib (Rinvoq) works for teenagers and adults with moderate to severe eczema in real-life settings in China. You will take the medication as prescribed by your doctor, and researchers will track your symptoms and quality of life through apps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older (if between 12 and 17, you must weigh at least 40 kg / 88 lbs)
- You have been diagnosed with moderate to severe eczema (atopic dermatitis) by a doctor
- Your doctor has already decided to prescribe the study drug (upadacitinib) for your eczema before you were asked about this study
- You have never taken upadacitinib (Rinvoq) before
- You are not in any other treatment research study right now
- You are willing to use apps to report your symptoms and experiences
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.